Travere Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric Dube
- Full Time Employees
- 497
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3611 Valley Centre Drive San Diego CA United States of America 92130
- IPO Date
- Nov 8, 2012
- CIK
- 0001438533
- Website
- travere.com
- Similar Companies
- Business
- Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for people living with rare kidney and metabolic diseases. The company’s core products include FILSPARI® (sparsentan), a dual endothelin angiotensin receptor antagonist approved for the treatment of IgA nephropathy (IgAN), and pipeline therapies targeting focal segmental glomerulosclerosis (FSGS) and classical homocystinuria (HCU). Travere’s offerings encompass rare kidney disease treatments and metabolic disorder therapies, supported by late-stage clinical programs and regulatory approvals primarily in the United States and Europe. The company also emphasizes disease-modifying therapies and aims to improve access to care for underserved patient populations. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics operates globally, engaging with expert communities and rare disease patients to accelerate development and delivery of innovative medicines. In recent years, the company divested its bile acid product portfolio in 2023 to focus its resources on kidney and metabolic rare disorders. Key recent developments include full FDA approval of FILSPARI for IgAN, an expanded regulatory label with streamlined Risk Evaluation and Mitigation Strategy (REMS) requirements, and ongoing preparations to restart enrollment for pegtibatinase, a potential first disease-modifying therapy for classical homocystinuria. The company also reported strong commercial momentum for FILSPARI with significant increases in net product sales, exceeding $226 million for full year 2024 and demonstrating robust growth into 2025. Strategic initiatives include advancing late-stage clinical trials for rare kidney diseases such as FSGS, with recent submissions to the FDA based on positive Phase 3 data, and launching educational campaigns like “Play It Forward” to raise awareness and support for the rare kidney disease community. Travere actively pursues partnerships and collaborations focused on addressing unmet needs in rare diseases while promoting diversity and inclusion through initiatives like the Rare Disease Diversity Coalition, targeting racial and socioeconomic disparities in care access. Its operations reflect a patient-centric approach, supported by more than 450 employees, including rare disease survivors and caregivers. Overall, Travere Therapeutics leverages its specialized expertise in rare kidney and metabolic disorders to deliver a focused portfolio of transformative therapies and engage in strategic clinical and commercial expansion, solidifying its position as a leader in rare disease treatment innovation. This description encompasses Travere Therapeutics’ main products and services, recent operational and strategic changes, industry focus, geographic presence, founding details, and its ongoing commitment to patients with rare diseases.
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript
Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes